Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

An Inhalable Rapamycin Formulation for Treating Age-Related Conditions

a technology of rapamycin and inhalation, which is applied in the direction of drug compositions, respiratory disorders, anti-noxious agents, etc., can solve the problems of affecting the quality of life, and increasing cancer risk, so as to reduce the toxicity of rapamycin and the associated drug concentration, inhibit the signaling of mtor, and reduce the effect of toxicity

Inactive Publication Date: 2017-01-19
LAM THERAPEUTICS
View PDF5 Cites 18 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention is a safe and effective aerosol formulation of a rapamycin composition that can deliver the drug to target tissues with minimal toxicity. The formulation is designed to produce high concentrations of drug in the lung tissue, which is the site of action for rapamycin. This results in a lower systemic exposure to the drug and improved safety compared to other dosage forms. The formulation also displays effective biological activity, inhibiting cell growth and viability in the target tissues. These results indicate that the aerosol formulation is capable of delivering a low, but therapeutically effective, dose of rapamycin with high efficacy. Overall, this invention provides a safer and effective formulation of rapamycin for targeted delivery with low systemic exposure and improved therapeutic efficacy.

Problems solved by technology

Rapamycin use in its clinically approved context has several known adverse effects including lung toxicity (the RAPAMUNE label warns that it is not indicated for lung transplant patients), increased cancer risk, and diabetes-like symptoms.
In addition, a 2012 meta-analysis concluded that 10% of cancer patients administered temsirolimus or everolimus may experience mild grade toxicity with a worsening of quality of life and, in some case, interruption of therapy.
In view of the wide-spread recognition of the potential for rapamycin-induced lung toxicity, a pharmaceutical composition comprising rapamycin for pulmonary delivery was not considered to be a viable therapeutic option in humans.
The '569 application does not provide any animal data in support of its methods of treating or preventing an age-related disease, condition, or disorder.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • An Inhalable Rapamycin Formulation for Treating Age-Related Conditions
  • An Inhalable Rapamycin Formulation for Treating Age-Related Conditions
  • An Inhalable Rapamycin Formulation for Treating Age-Related Conditions

Examples

Experimental program
Comparison scheme
Effect test

example 1

Aqueous Aerosol Formulation

[0195]An exemplary aqueous formulation of rapamycin was prepared using the following components.

ComponentAmount (g)Mass Fraction (w / w)rapamycin0.10.01%  ethanol25025%propylene glycol25025%polysorbate 800.020.002%  water50050%Total1000

[0196]Blending Procedure: in a 1000 ml amber volumetric flask, blend 250 propylene glycol with 250 ethanol until uniform. Then sequentially dissolve first 100 mg rapamycin then 20 mg polysorbate 80 in the propylene glycol and ethanol solution. Add water to bring the volumetric to 1000 ml and stir or sonicate until uniform and all the rapamycin is dissolved. Store at controlled temperature away from light.

example 2

Dry Powder Formulation

[0197]Batch 06RP68.HQ00008 and 06RP68.HQ00009. These two formulations are each a blend of micronized drug (rapamycin) particles dispersed onto the surface of lactose carrier particles. The final composition of each batch comprises 1% (w / w) drug particles having a mean diameter of about 2.60 microns and 3.00 microns, respectively. Drug particles having a suitable size range are made by wet polishing (06RP68.HQ00008) or jet milling (06RP68.HQ00009), as described below. While this example used 1% (w / w) rapamycin, a range 0.5 to 20% is practicable. The carrier particles consist of a blend of two carriers, Respitose® SV003, present at 95.5% (w / w) and having particle sizes of about 30 to 100 microns (equivalent spherical diameter), and Respitose® LH300 (Lactohale 300) present at 5.5% (w / w) and having particle sizes less than 10 microns (equivalent spherical diameter). After blending, the blends were assayed to confirmed homogeneity and drug content of 1%.

[0198]To red...

example 3

Determination of Rapamycin in Lung and Blood Following Administration by Oropharyngeal Aspiration (OPA) and Oral Gavage to C57BL6 Mice

[0201]This study was conducted to evaluate the concentration of rapamycin in male C57BL / 6 mice after administration of rapamycin at a very high target dose of 1 mg / kg by gavage and oropharyngeal aspiration (OPA). A method for the analysis of rapamycin in mouse blood and lung homogenate was developed using liquid chromatography with tandem mass spectrometry detection (LC-MS / MS). Calibration curves of rapamycin using triplicate concentrations were analyzed between 1 ng / mL and 2000 ng / mL in mouse blood, and between 2 ng / mL and 20,000 ng / mL in mouse lung homogenate. Accuracy, precision and linearity were within expected ranges.

[0202]In pilot studies, the efficiency of vehicle delivery to the lungs via oropharyngeal aspiration with a volume of 50 μL per mouse was evaluated by administration of Evans Blue dye. The presence of blue dye only in lungs was veri...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
mean diameteraaaaaaaaaa
mean diameteraaaaaaaaaa
concentrationsaaaaaaaaaa
Login to View More

Abstract

The present invention relates to methods and compositions for anti-aging therapy and for the treatment and prophylaxis of age-related diseases and disorders in a human subject in need of such therapy or treatment, the methods comprising the pulmonary administration to the subject, preferably via inhalation, of composition comprising rapamycin, or a prodrug or derivative thereof.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]The current application claims priority under 35 U.S.C. §119(e) to provisional application Ser. No. 61 / 975,127 filed Apr. 4, 2014, the disclosure of which is incorporated herein by reference in its entirety.FIELD OF THE INVENTION[0002]The present invention relates to methods and pharmaceutical compositions for pulmonary delivery by inhalation, the compositions comprising rapamycin for anti-aging and for the prophylaxis and treatment of age-related conditions, diseases, and disorders.BACKGROUND OF THE INVENTION[0003]Rapamycin is a macrocyclic triene antibiotic produced by Streptomyces hygroscopicus. See e.g., U.S. Pat. No. 3,929,992. Rapamycin is an inhibitor of mTOR. The immunosuppressive and anti-inflammatory properties of rapamycin initially indicated its use in the transplantation field and in the treatment of autoimmune diseases. For example, it was shown to prevent the formation of humoral (IgE-like) antibodies in response to an albu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K9/00A61K31/436
CPCA61K31/436A61K9/0075A61K9/145A61K45/06A61P11/00A61P35/00A61P39/06A61P43/00A61K9/0053A61K9/14A61K47/12A61K47/24A61K47/26
Inventor ARMER, THOMASMELVIN, LAWRENCE S.ROTHBERG, JONATHAN M.LICHENSTEIN, HENRI
Owner LAM THERAPEUTICS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com